Royal Marsden Hospital / The Royal Marsden NHS Foundation Trust

WHO 2022 landscape of papillary and chromophobe renal cell carcinoma (2022) Lobo J, Ohashi R, Amin MB, Berney DM, Compérat EM, Cree IA, Gill AJ, et al. Journal article, Review article A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer (2021) Kaidar-Person O, Dahn HM, Nichol AM, Boersma LJ, de Ruysscher D, Meattini I, Pignol JP, et al. Journal article Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party (2021) Hayden PJ, Eikema DJ, De Wreede LC, Koster L, Kroger N, Einsele H, Minnema M, et al. Journal article INTERNATIONAL EXPERT DELPHI CONSENSUS GUIDELINES FOR THE USE OF BOLUS IN POST MASTECTOMY RADIATION THERAPY (2021) Dahn H, Boersma L, De Ruysscher D, Meattini I, Offersen B, Pignol JP, Aristei C, et al. Conference contribution THE USE OF BOLUS IN POSTMASTECTOMY RADIATION THERAPY FOR BREAST CANCER: A SYSTEMATIC REVIEW (2021) Dahn H, Boersma L, De Ruysscher D, Meattini I, Offersen B, Pignol JP, Belkacemi Y, et al. Journal article The use of bolus in postmastectomy radiation therapy for breast cancer: A systematic review (2021) Dahn HM, Boersma LJ, de Ruysscher D, Meattini I, Offersen BV, Pignol JP, Aristei C, et al. Journal article, Review article High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE (2021) Harbeck N, Johnston S, Fasching P, Martin M, Toi M, Rastogi P, Song C, et al. Conference contribution Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al. Journal article PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021) Girard N, Smit HJM, Sibille A, Mcdonald F, Mornex F, Garassino MCC, Filippi AR, et al. Conference contribution